glp 1 weight loss non diabetic cost Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for Long-term Success of GLP-1s Hinges

1501 Westcliff Dr

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

Bob Gabbay, endocrinologist, researcher, and former Chief Scientific and Medical Officer of the American Diabetes Association, as he explores the most exciting topics and latest innovations in diabetes care

supporting the system internally When you support your bodys natural processes: signaling pathways remain connected the microbiome continues to adapt and improve digestion becomes more consistent over time This approach focuses on resilience, not reliance